Therefore, although the intrinsic role of galectin-9 on glioma cells has not yet been elucidated, its effects on the glioma microenvironment suggest a potential role of this lectin as an immunotherapeutic target, alternative to the PD1/PD-L1 pathway. The gene discussed is LGALS9; the disease is glioma.